Literature DB >> 21721043

Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder.

Kumiko Kikuchi1, Jun-ichi Iga, Sumiko Tayoshi, Masahito Nakataki, Shinya Watanabe, Shusuke Numata, Tetsuro Ohmori.   

Abstract

OBJECTIVES: Vascular endothelial growth factor (VEGF) is thought to be involved in the pathophysiology of mood disorders and the target of antidepressants. The aim of this study was to elucidate molecular effects of lithium on VEGF expression by using leukocytes of healthy subjects and patients with bipolar disorder.
METHODS: Eight healthy male subjects participated in the first study. Lithium was prescribed for 2 weeks, enough to reach therapeutic serum concentration. Leukocyte counts and serum lithium concentrations were determined at baseline, at 1- and 2-week medication, and at 2 weeks after stopping medication. VEGF mRNA levels were also examined in nine lithium-treated bipolar patients and healthy controls in the second study.
RESULTS: In the first study, leukocyte counts were significantly increased at 2 weeks compared with those at baseline and were normalized after 2 weeks. VEGF mRNA levels were significantly decreased at 2 weeks and after 2 weeks compared with those at baseline. Consistent with the first study, VEGF mRNA levels were significantly decreased in the lithium-treated bipolar patients compared with healthy controls.
CONCLUSIONS: Our investigation suggests that VEGF mRNA expression may be useful as a peripheral marker of the effects of lithium.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21721043     DOI: 10.1002/hup.1215

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

1.  A novel relationship for schizophrenia, bipolar and major depressive disorder Part 5: a hint from chromosome 5 high density association screen.

Authors:  Xing Chen; Feng Long; Bin Cai; Xiaohong Chen; Gang Chen
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

Review 2.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 3.  Current state of biomarkers in bipolar disorder.

Authors:  Gustavo Scola; Ana Cristina Andreazza
Journal:  Curr Psychiatry Rep       Date:  2014-12       Impact factor: 5.285

Review 4.  Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank.

Authors:  Elizabeth Scarr; Mark J Millan; Sabine Bahn; Alessandro Bertolino; Christoph W Turck; Shitij Kapur; Hans-Jürgen Möller; Brian Dean
Journal:  Int J Neuropsychopharmacol       Date:  2015-04-21       Impact factor: 5.176

Review 5.  Coding and noncoding gene expression biomarkers in mood disorders and schizophrenia.

Authors:  Firoza Mamdani; Maureen V Martin; Todd Lencz; Brandi Rollins; Delbert G Robinson; Emily A Moon; Anil K Malhotra; Marquis P Vawter
Journal:  Dis Markers       Date:  2013-07-21       Impact factor: 3.434

6.  Neurotrophic factors in bipolar disorders patients with manic episode

Authors:  Özgür Korhan Tunçel; Gökhan Sarisoy; Eda Çetin; Ebru Kaynar Tunçel; Birşen Bilgici; Arzu Karaustaoğlu
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.